Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 8 Summary of studies that examined the safety of treatment interventions for people with diabetes

From: Safety and efficacy of tinea pedis and onychomycosis treatment in people with diabetes: a systematic review

Study Design Subjects Infection Organism Intervention Assessment (week)
Gupta [42] RCT Itraconazole
N = 35
Sex = 16 M; 19 F
Age = 57.77 (2.3) yr
Terbinafine
N = 35
Sex = 18 M; 17 F
Age = 63.65 (1.9) yr
DLSO Dermatophyte Ciclopirox 8%
Ciclopirox 8% nail lacquer applied to nail and 5 mm surrounding skin. Daily application over the previous coat, removed after 7 days using isopropyl alcohol. Nails trimmed and debrided at each scheduled visit (8 weeks)
48
Brenner [43] Case series N = 49
Sex = 36 M; 13 F
Age = 63.8 (12.0) yr
Duration of diabetes = 8.4 (7.4) yr
Duration of infection = 10.8 (15.3) yr
DSO†† Not reported Terbinafine
250 mg terbinafine daily 12 weeks
48
Farkas [46] Case series N = 89
Sex = 47 M; 42 F
Age = 55.7 (11.7) yr
Duration of diabetes = 10.2 (7.7)
Duration of infection = 5.4 (6.0)
DSO Dermatophyte (67.4%); moulds (5.6%); yeast (4.5%) Itraconazole pulse therapy 200 mg of oral itraconazole taken twice a day for the first week of three consecutive months Terbinafine 250 mg of oral terbinafine once daily for 12 weeks. 48
Sadighha [41] Case series N = 13
Sex = NR
Age = NR
DSO†† Dermatophyte Pulse itraconazole therapy 200 mg of oral itraconazole taken twice a day for the first week of four consecutive months 26
  1. Concomitant tinea pedis was present.
  2. "DSO" = distal subungual onychomycosis; "DLSO" = distal lateral subungual onychomycosis
  3. Study 4 is excluded from the graph because efficacy was not assessed at week 48 like the rest of the studies. Sadighha [41] found itraconazole achieved cure in 7.7% (1/13) of patients with diabetes at week 26